Michael Levy

Michael Levy

Auto-generated profile, based on publicly available information

Michael Levy

Department of Neurology, Mass General Brigham, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2018 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
SJS. Jarius
S. Jarius
Friedemann PaulFriedemann Paul
Friedemann Paul
OAOrhan Aktas
Orhan Aktas
NAN. Asgari
N. Asgari
RDRussell C. Dale
Russell C. Dale
BWB. Wildemann
B. Wildemann
Over the past few years, new-generation cell-based assays have demonstrated a robust association of autoantibodies to full-length human myelin oligodendrocyte glycoprotein (MOG-IgG) with (mostly recurrent) optic neuritis, myelitis and brainstem encephalitis, as well as with acute disseminated encephalomyelitis (ADEM)-like presentations. Most experts now consider MOG-IgG-associated encephalomyelitis (MOG-EM) a disease entity in its own right, immunopathogenetically distinct from both classic multiple sclerosis (MS) and aquaporin-4 (AQP4)-IgG-positive neuromyelitis optica spectrum disorders (NMOSD). Owing to a substantial overlap in clinicoradiological presentation, MOG-EM was often unwittingly misdiagnosed as MS in the past. Accordingly, increasing numbers of patients with suspected or established MS are currently being tested for MOG-IgG. However, screening of large unselected cohorts for rare biomarkers can significantly reduce the positive predictive value of a test. To lessen the hazard of overdiagnosing MOG-EM, which may lead to inappropriate treatment, more selective criteria for MOG-IgG testing are urgently needed. In this paper, we propose indications for MOG-IgG testing based on expert consensus. In addition, we give a list of conditions atypical for MOG-EM (“red flags”) that should prompt physicians to challenge a positive MOG-IgG test result. Finally, we provide recommendations regarding assay methodology, specimen sampling and data interpretation.

1 September 2012 in Archives of Neurology
Verified
Journal Article
Open access
PDF file
MMMaureen A. Mealy
Maureen A. Mealy
DWDean M. Wingerchuk
Dean M. Wingerchuk
BGBenjamin Greenberg
Benjamin Greenberg
MLMichael Levy
Michael Levy
Research from JAMA Neurology — Epidemiology of Neuromyelitis Optica in the United States — A Multicenter Analysis

1 October 2012 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
DKDorlan J. Kimbrough
Dorlan J. Kimbrough
KFKazuo Fujihara
Kazuo Fujihara
AJAnu Jacob
Anu Jacob
MLMarco A. Lana-Peixoto
Marco A. Lana-Peixoto
MLMaria Isabel Leite
Maria Isabel Leite
DWDean M. Wingerchuk
Dean M. Wingerchuk

5 April 2023 in Annals of Neurology
Verified
Journal Article
Open access
SPSean J. Pittock
Sean J. Pittock
MBMichael Barnett
Michael Barnett
JBJeffrey L. Bennett
Jeffrey L. Bennett
ABAchim Berthele
Achim Berthele
JSJérôme de Sèze
Jérôme de Sèze
HKHo Jin Kim
Ho Jin Kim
Objective: CHAMPION‐NMOSD (NCT04201262) is a phase 3, open‐label, externally controlled interventional study evaluating the efficacy and safety of the terminal complement inhibitor ravulizumab in adult patients with anti–aquaporin‐4 antibody–positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD). Ravulizumab binds the same complement component 5 epitope as the approved therapeutic eculizumab but has a longer half‐life, enabling an extended dosing interval (8 vs 2 weeks).Methods: The availability of eculizumab precluded the use of a concurrent placebo control in CHAMPION‐NMOSD; consequently, the placebo group of the eculizumab phase 3 trial PREVENT (n = 47) was used as an external comparator. Patients received weight‐based intravenous ravulizumab on day 1 and maintenance doses on day 15, then once every 8 weeks. The primary endpoint was time to first adjudicated on‐trial relapse.Results: The primary endpoint was met; no patients taking ravulizumab (n = 58) had an adjudicated relapse (during 84.0 patient‐years of treatment) versus 20 patients with adjudicated relapses in the placebo group of PREVENT (during 46.9 patient‐years; relapse risk reduction = 98.6%, 95% confidence interval = 89.7%–100.0%,p < 0.0001). Median (range) study period follow‐up time was 73.5 (11.0–117.7) weeks for ravulizumab. Most treatment‐emergent adverse events were mild/moderate; no deaths were reported. Two patients taking ravulizumab experienced meningococcal infections. Both recovered with no sequelae; one continued ravulizumab treatment.Interpretation: Ravulizumab significantly reduced relapse risk in patients with AQP4+ NMOSD, with a safety profile consistent with those of eculizumab and ravulizumab across all approved indications. ANN NEUROL 2023;93:1053–1068

1 October 2018 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
RNRam Narayan
Ram Narayan
ASAlexandra Simpson
Alexandra Simpson
KFKatelyn Fritsche
Katelyn Fritsche
SSSara Salama
Sara Salama
SPSantiago Pardo
Santiago Pardo
MLMichael Levy
Michael Levy

16 November 2021 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PDF file
MRMarius Ringelstein
Marius Ringelstein
IAIlya Ayzenberg
Ilya Ayzenberg
GLGero Lindenblatt
Gero Lindenblatt
KFKatinka Fischer
Katinka Fischer
AGAnna Gahlen
Anna Gahlen
O(on behalf of the Neuromyelitis Optica Study Group (NEMOS)
on behalf of the Neuromyelitis Optica Study Group (NEMOS)
Background and Objectives To evaluate the long-term safety and efficacy of tocilizumab (TCZ), a humanized anti–interleukin-6 receptor antibody in myelin oligodendrocyte glycoprotein–IgG–associated disease (MOGAD) and neuromyelitis optica spectrum disorders (NMOSD). Methods Annualized relapse rate (ARR), Expanded Disability Status Scale score, MRI, autoantibody titers, pain, and adverse events were retrospectively evaluated in 57 patients with MOGAD (n = 14), aquaporin-4 (AQP4)-IgG seropositive (n = 36), and seronegative NMOSD (n = 7; 12%), switched to TCZ from previous immunotherapies, particularly rituximab. Results Patients received TCZ for 23.8 months (median; interquartile range 13.0–51.1 months), with an IV dose of 8.0 mg/kg (median; range 6–12 mg/kg) every 31.6 days (mean; range 26–44 days). For MOGAD, the median ARR decreased from 1.75 (range 0.5–5) to 0 (range 0–0.9; p = 0.0011) under TCZ. A similar effect was seen for AQP4-IgG+ (ARR reduction from 1.5 [range 0–5] to 0 [range 0–4.2]; p < 0.001) and for seronegative NMOSD (from 3.0 [range 1.0–3.0] to 0.2 [range 0–2.0]; p = 0.031). During TCZ, 60% of all patients were relapse free (79% for MOGAD, 56% for AQP4-IgG+, and 43% for seronegative NMOSD). Disability follow-up indicated stabilization. MRI inflammatory activity decreased in MOGAD (p = 0.04; for the brain) and in AQP4-IgG+ NMOSD (p < 0.001; for the spinal cord). Chronic pain was unchanged. Regarding only patients treated with TCZ for at least 12 months (n = 44), ARR reductions were confirmed, including the subgroups of MOGAD (n = 11) and AQP4-IgG+ patients (n = 28). Similarly, in the group of patients treated with TCZ for at least 12 months, 59% of them were relapse free, with 73% for MOGAD, 57% for AQP4-IgG+, and 40% for patients with seronegative NMOSD. No severe or unexpected safety signals were observed. Add-on therapy showed no advantage compared with TCZ monotherapy. Discussion This study provides Class III evidence that long-term TCZ therapy is safe and reduces relapse probability in MOGAD and AQP4-IgG+ NMOSD.